阅读说明：本技术 用于治疗注意力缺陷多动障碍的哌甲酯组合物 (Methylphenidate compositions for the treatment of attention deficit hyperactivity disorder ) 是由 J·戈布鲁 D·利克利斯 B·J·因克尔登 R·戈梅尼 于 2020-01-24 设计创作，主要内容包括：描述了一种固体口服药物组合物。所述固体口服药物组合物包括哌甲酯或其药用盐,其中所述固体口服药物组合物的体内吸收模型具有选自以下的函数：单威布尔函数、双威布尔函数和sigmoid eMax函数。所述固体口服药物组合物的体外溶出的多个分数与固体口服药物组合物的体内吸收的同一多个分数的相关性是非线性的。还描述了一种治疗患有对施用哌甲酯有反应的障碍或病症的受试者的病症的方法。所述方法包括向所述受试者口服施用有效量的所述固体口服药物组合物。(A solid oral pharmaceutical composition is described. The solid oral pharmaceutical composition comprises methylphenidate or a pharmaceutically acceptable salt thereof, wherein the model of in vivo absorption of the solid oral pharmaceutical composition has a function selected from the group consisting of: a single weibull function, a double weibull function, and a sigmoid eMax function. The correlation of the multiple fractions of in vitro dissolution of the solid oral pharmaceutical composition to the same multiple fractions of in vivo absorption of the solid oral pharmaceutical composition is non-linear. Also described is a method of treating a disorder in a subject having a disorder or condition responsive to administration of methylphenidate. The method comprises orally administering to the subject an effective amount of the solid oral pharmaceutical composition.)